Literature DB >> 2432918

Immunosuppressive properties of pregnancy serum on the mixed lymphocyte reaction.

N S Nicholas, G S Panayi.   

Abstract

The human fetus may escape immunological attack because of serum factors which have immunomodulatory influence on maternal cellular effector responses. Paired peripheral and retroplacental sera were shown to inhibit the allogenic mixed lymphocyte reaction (MLR) used as an in-vitro model of cell-mediated immunity. There was no correlation between the suppressive effect of the peripheral and retroplacental sera and the serum concentrations of four pregnancy-related proteins (alpha-fetoprotein, pregnancy-associated alpha 2 glycoprotein, pregnancy-associated plasma protein A and Schwangerschaftsprotein 1) to which immunosuppressive properties have been ascribed, but there was a negative correlation between peripheral AFP and MLR inhibition (r = -0.62, P less than 0.001). Hence, the factor or factors responsible for suppressing the MLR are not those investigated in the present study.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2432918     DOI: 10.1111/j.1471-0528.1986.tb07860.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  4 in total

1.  Postpartum autologous plasma transfusion: effect on RA.

Authors:  C D Scoville
Journal:  Ann Rheum Dis       Date:  1992-12       Impact factor: 19.103

2.  Interpretation of blocking activity in maternal serum depends on the equation used for calculation of mixed lymphocyte culture results.

Authors:  M I Park; S S Edwin; J R Scott; D W Branch
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

3.  The immunomodulatory activity of human amniotic fluid can be correlated with transforming growth factor-beta 1 (TGF-beta 1) and beta 2 activity.

Authors:  A K Lang; R F Searle
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

4.  Mitotic quiescence in hepatic cancer stem cells: An incognito mode.

Authors:  Kandasamy Ashokachakkaravarthy; Biju Pottakkat
Journal:  Oncol Rev       Date:  2020-02-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.